Vector Science and Therapeutics Corp. PAIN

Mequon, Wisconsin--(Newsfile Corp. - September 25, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors has approved the grant of 150,000 stock options (the "Options") to an Officer of the Company in accordance with the Company's stock option plan. The Options vest in 25% tranches over a three year period, have an exercise price of C$1.80 and are exercisable for a period of five years from the date of grant. This...

Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") is pleased to announce that the Company has entered into an investor relations agreement (the "IR Agreement") with RedChip Companies, Inc. ("RedChip") through its principal, Dave Gentry, dated August 24, 2026.

Vector Science & Therapeutics Corp. (TSXV: PAIN) (the "Company") today announced that the first of four planned manufacturing suites at its LyoGenesis Manufacturing facility is now producing pharma-grade peptides, putting the Company on track to begin fulfilling Vector's existing customer orders for nine peptides this month.

Vector Science and Therapeutics Corp. ("Vector" or the "Company") (TSXV: PAIN) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office covering an integrated platform intended to improve tissue healing across orthopedic surgical care.

Verlytix, a global contract testing laboratory serving the pharmaceutical and biotechnology industries, today announced the launch of its expanded quality analytical testing platform. Verlytix is a related company to LyoGenesis Manufacturing, reflecting continued growth, an expanding scope of services, and a long-term commitment to quality, precision, and analytical excellence across the drug product lifecycle.

Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") announced today that its subsidiary, Vector Science and Therapeutics Operating Corp. ("VST"), has entered into an Amended and Restated Exclusive License and Manufacturing Agreement (the "Agreement"), effective August 13, 2026, with LyoGenesis Holdings LLC ("LyoGenesis"), amending and restating the parties' prior agreement dated July 6, 2026.

LyoGenesis Plus 1, LLC ("LyoGenesis Plus"), a company related to Vector Science & Therapeutics Corp. ("Vector"), and Wynn Pharmaceuticals LLC ("Wynn") today announced they have entered into a Memorandum of Understanding (MOU) to collaborate on the development and manufacture of a new line of IV bag and vial adaptor products.

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the filing of its first quarterly financial statements and Management's Discussion & Analysis since completing its going-public transaction through a reverse takeover with OpenSesame Acquisition Corp. on April 23, 2026. The full filings are available under the Company's profile on SEDAR+ at www.sedarplus.ca.

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced plans to build a dedicated distributor network to support commercialization of its peptide portfolio across the orthopedic, sports, and regenerative medicine channels. The portfolio is focused on the clinical areas of musculoskeletal conditions, soft tissue injury, and degenerative joint disease, including osteoarthritis. The specialized force is designed to place the Company's peptide-based recovery off

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector") and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMist™, Vector's localized atomized drug delivery platform, and The LASSO Protocol™ (Laparoscopic Atomization System for Sparing Opioids).

Vector Science & Therapeutics, Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the expansion of its intellectual property portfolio to 15 patent applications developed and filed over approximately the past two years, establishing a broad technology estate centered on one of medicine's most persistent challenges: delivering therapeutic agents — including peptides and other biologics that are frequently difficult to administer outside the gastrointestinal tract — to the right tissue